By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


Company News
Ablynx (ABLYF) To Receive €8 Million Milestone As Boehringer Ingelheim Starts First Patient Study With A Bi-Specific Nanobody In Oncology 1/29/2016 8:55:35 AM
Ablynx (ABLYF) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/7/2016 10:34:04 AM
Ablynx (ABLYF) Completes Enrolment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants 12/17/2015 10:22:01 AM
Ablynx (ABLYF) Appoints Robert K. Zeldin, MD, Chief Medical Officer 11/30/2015 11:16:25 AM
Ablynx (ABLYF), Novo Nordisk A/S (NVO) Ink Nanobody Pact Worth $399 Million+ 11/25/2015 10:07:32 AM
Ablynx (ABLYF) Provides Business Update For The First Nine Months Of 2015 11/18/2015 9:39:05 AM
Ablynx (ABLYF)’s Partner Boehringer Ingelheim Presented Positive In Vivo Proof-Of-Mechanism Data With Bi-Specific Nanobody At Euro Global Summit On Cancer Therapy 11/5/2015 10:54:42 AM
Ablynx (ABLYF) Achieves First Milestone In Immuno-Oncology Collaboration With Merck & Co. (MRK) 10/15/2015 10:56:08 AM
Ablynx (ABLYF) Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP, A Rare Blood Clotting Disorder 9/29/2015 9:01:25 AM
Ablynx (ABLYF) Announces Half-Year Results For 2015 8/27/2015 9:15:23 AM